• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers
Home / About Us / Management Team

Management Team

Celyad Oncology’s Management team consists of international experts whose talent, experience and commitment position the Company as a leader in the field of CAR T immunotherapy.

Management

Filippo Petti*

CHIEF EXECUTIVE OFFICER/CFO

Filippo Petti*

CHIEF EXECUTIVE OFFICER/CFO

Filippo Petti*

CHIEF EXECUTIVE OFFICER/CFO

Filippo Petti joined Celyad Oncology in September 2018 as the Chief Financial Officer, and was appointed Chief Executive Officer in April 2019 and continues to act as CFO. Prior to joining the Company, Mr. Petti worked in healthcare investment banking both at Wells Fargo Securities and William Blair & Company. Prior to his roles in investment banking, Filippo spent several years in equity research covering U.S. biotechnology companies both at William Blair & Company and Wedbush Securities. He began his career as a research scientist at OSI Pharmaceuticals, Inc. focused on drug discovery and translational research before transitioning into corporate development with the company. Mr. Petti holds a Master of Business Administration from Cornell University, a Master of Science from St. John’s University and a Bachelor of Science from Syracuse University.

Philippe Dechamps*

CHIEF LEGAL OFFICER

Philippe Dechamps*

CHIEF LEGAL OFFICER

Philippe Dechamps*

CHIEF LEGAL OFFICER

Philippe Dechamps joined Celyad Oncology in September 2016 and brings over 20 years of expertise in Corporate Affairs. He started his career at the Brussels Bar with De Bandt (now Linklaters) in 1994. He joined the legal team of Solvay in 1998 where he was mostly active in mergers and acquisitions. He then developed and managed the distribution contracts of the cardiovascular businesses of Guidant and Abbott in Europe, Middle East and Africa for more than five years, before leaving the pharma and medical device industry to join Delhaize Group in 2008, where he became General Counsel & Company Secretary in March, 2015. In this role Philippe was part of the senior leadership team that successfully negotiated and finalized the merger of Delhaize Group and Royal Ahold in July, 2016. Philippe holds a Master of Laws from the Harvard Law School, a Master of European Laws from the Vrije Universiteit Brussel and a Master of Laws from the Université Catholique de Louvain.

*Permanent representative of NandaDevi SRL

David Gilham*

CHIEF SCIENTIFIC OFFICER

David Gilham*

CHIEF SCIENTIFIC OFFICER

David Gilham*

CHIEF SCIENTIFIC OFFICER

Dr. David Gilham first joined Celyad Oncology in April 2016 as a member of the Scientific Advisory Board. He became Vice-President of R&D in September 2016 and was appointed Chief Scientific Officer in May 2020, heading the implementation of our research and development strategy for our programs in immuno-oncology. Dr. Gilham received his Ph.D. in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T cells with Professor Robert Hawkins. The group moved to Manchester in 1998 where his research activity has focused on engineering T cells for cancer therapy and developing the necessary pre-clinical studies to support translation of this therapy into Phase 1/2 clinical trials in Manchester. Prior to joining Celyad Oncology, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre.

Frédéric Lehmann*

VP CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS

Frédéric Lehmann*

VP CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS

Frédéric Lehmann*

VP CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS

Dr. Lehmann has extensive experience in oncology drug development spanning early to late phase, including clinical trial design, translational research, regulatory interactions, and clinical risk management. He is a physician by training and started his academic career at the Ludwig Institute for Cancer Research in Brussels, followed by a position at the Institute Jules Bordet. He then moved to the European Organization for Research and Treatment of Cancer (EORTC) as Medical Advisor. Dr. Lehmann began his corporate career at GlaxoSmithKline, where he led the early worldwide clinical development program for the Company’s cancer vaccines and went on to lead the research and development incubator for cancer immunotherapeutics. Dr. Lehmann qualified as an M.D. and has a Master’s degree in Hematology in Oncology.

*Permanent representative of ImXsense SRL

Philippe Nobels*

VP HUMAN RESOURCES

Philippe Nobels*

VP HUMAN RESOURCES

Philippe Nobels*

VP HUMAN RESOURCES

Philippe Nobels joined Celyad Oncology in late 2016. He started his career at Price Waterhouse (now PwC) as auditor in 1989. He also went in rotational assignment in Congo during two years on consulting missions for the World Bank. In 1995, he joined Fourcroy as plant controller. He then joined Dow Corning in 1997 where he held different positions in Finance and Human Resources. He led the HR operations in Europe, became the HR manager for Dow Corning in Belgium, and HR Business Partner for the sales and marketing functions globally. As a member of the sales and marketing leadership teams, he contributed to the company’s major transformation initiatives to increase organizational effectiveness, employees’ engagement and performance as well as business results. Philippe holds a master degree in Economics from the University of Namur.

*Permanent representative of MC Consult SRL

Stephen Rubino*

Chief Business Officer

Stephen Rubino*

Chief Business Officer

Stephen Rubino*

Chief Business Officer

Dr. Rubino brings over 30 years of pharmaceutical leadership experience to the role of Chief Business Officer of Celyad Oncology with emphasis in the areas of business development & licensing, new product development, commercial operations, pharmaceutical strategy and investor relations. Dr. Rubino currently serves as Independent Board Member of ILKOS Therapeutics and Sermonix Pharmaceuticals. Dr. Rubino has also served Novartis Pharmaceuticals in a wide range of roles and therapeutic areas, the last of which was as Global Head of Business Development and New Product Marketing, responsible for developing and building the product pipeline for Novartis’ Cell & Gene Therapies Unit. Prior to Novartis, Dr. Rubino worked for Schering–Plough (Merck) where his last role was head of the Global Solid Tumor Oncology & Autoimmune Business Unit responsible for the licensing and launch of Remicade, as well as the launch and commercialization of several global oncology brands. Dr. Rubino received his Ph.D. from Weill Cornell University and his M.B.A. from Baruch University.

Peggy Sotiropoulou

HEAD OF RESEARCH & DEVELOPMENT

Peggy Sotiropoulou

HEAD OF RESEARCH & DEVELOPMENT

Peggy Sotiropoulou

HEAD OF RESEARCH & DEVELOPMENT

Dr. Peggy Sotiropoulou joined Celyad Oncology in October 2017, bringing 15 years of experience in oncology and immuno-oncology. Dr. Sotiropoulou joined Celyad Oncology initially as R&D Manager, evolving to R&D Director in October 2018. In May 2020, Dr. Sotiropoulou was appointed Head of R&D, where she oversees a broad-range research program that aims to develop new strategies in CAR T cell designs to target hematological and solid malignancies. Dr. Sotiropoulou received her PhD in Cancer Immunotherapy from the Medical faculty of the University of Crete, prior to moving to the group of Professor Cédric Blanpain in the Université Libre de Bruxelles to investigate cancer development and the role of cancer stem cells. Prior to joining Celyad Oncology, Dr. Sotiropoulou was tenured Research Associate Professor in the Université Libre de Bruxelles, leading cutting-edge research on the response and sensitization of recalcitrant tumors to therapy.

Elena Spanjaard

Head of Global Quality & Regulatory

Elena Spanjaard

Head of Global Quality & Regulatory

Elena Spanjaard

Head of Global Quality & Regulatory

Dr. Elena Spanjaard joined Celyad Oncology in August 2018 as the Global Head of Regulatory Affairs. In May 2020, she assumed responsibility for Quality Assurance in addition to Regulatory Affairs. Prior to joining Celyad Oncology, Elena led global regulatory strategy for the allogeneic CAR T portfolio at Pfizer in collaboration with Servier and Cellectis. During Elena’s time at Pfizer, she specialized in early immuno-oncology and combination development. Elena’s career has spanned all stages of development in a variety of therapeutic areas including oncology, autoimmune and rare diseases. Elena began her Regulatory career in early development of immuno-oncology cell therapies at Dana-Farber Cancer Institute where she developed strong expertise in T cell manufacturing and characterization. Trained in Immunology, Elena earned her PhD from Boston University School of Medicine.

*Executive Committee Member

Board Of Directors

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy